Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces CEO leadership transition

eqs_en 
0 0 07.10.19
DGAP-Adhoc: QIAGEN N.V.: QIAGEN announces CEO leadership transition: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24065/Qiagen_Logo.svg.png
 

DGAP-Ad-hoc: QIAGEN N.V. / Key word(s): Personnel
QIAGEN N.V.: QIAGEN announces CEO leadership transition

07-Oct-2019 / 22:04 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

English Version

Ad-hoc Announcement pursuant to Article 17 Market Abuse Regulation

QIAGEN announces CEO leadership transition

Venlo, The Netherlands, October 7, 2019 - QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announces that Peer M. Schatz, Chief Executive Officer, has notified the Company that he has decided to step down as Chief Executive Officer and Chairman of the Management Board. He will remain with QIAGEN as Advisor to the Supervisory Board and transition into this role in the coming weeks. The Supervisory Board will now start a search for a permanent CEO. In the meantime, Thierry Bernard, Senior Vice President, Head of Molecular Diagnostics Business Area, will now act as interim CEO and work in tandem with Roland Sackers, Chief Financial Officer.

QIAGEN N.V.

Hulsterweg 82

5912 PL Venlo

The Netherlands

ISIN: NL0012169213

Frankfurt Stock Exchange, regulated market (Prime Standard)

Contact

John Gilardi

Vice President, Head of Corporate Communications and Investor Relations

+49 2103 29 11711 and +1 240 686 2222

[email protected]

07-Oct-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
Language: English
Company: QIAGEN N.V.
Hulsterweg 82
5912 PL Venlo
Netherlands
Phone: +31 7735566 - 00
Fax: +31 77 35566-58
E-mail: [email protected]
Internet: www.qiagen.com
ISIN: NL0012169213
WKN: A2DKCH
Indices: MDAX, TecDAX
Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, Chicago, NYSE, SIX
EQS News ID: 886527

 
End of Announcement DGAP News Service

886527  07-Oct-2019 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=886527&application_name=news&site_id=sharewise

QIAGEN NV Stock

€40.47
-0.150%
The price for the QIAGEN NV stock decreased slightly today. Compared to yesterday there is a change of -€0.060 (-0.150%).
With 12 Buy predictions and not the single Sell prediction the community is currently very high on QIAGEN NV.
With a target price of 47 € there is a slightly positive potential of 16.14% for QIAGEN NV compared to the current price of 40.47 €.
Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!